BMY
Bristol-Myers Squibb Company
BMY Institutional Purchase & Sale
Bristol-Myers Squibb Company Buys & Sells (2024 Q2)
- # of activities:
- 7
- AVG reported price*:
- $45.16
- Current price*:
- +49.07%($67.32)
7 value investing gurus have made changes to the Bristol-Myers Squibb Company (BMY) position according to the gurus' 2024 Q2 SEC quarterly report(s). BMY has been bought (as a new position) by 2, completely sold out by 2 guru(s), the number of BMY shares has been increased by 1, decreased by 2 super investor(s).
Which gurus or hedge funds bought BMY in 2024 Q2?
According to the 2024 Q2 SEC filing(s) Bristol-Myers Squibb Company (BMY) has been bought by 3 gurus / funds: Richard Pzena - Pzena Investment Management (added shares +14.97%), Sarah Ketterer - Causeway Capital Management (new buy) and Mark A. Hillman - Hillman Value Fund (new buy).
To see more about who is investing in Bristol-Myers Squibb Company (BMY), please go to the BMY ownership page.
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* AVG reported price: weighted average based on position sizes. Larger holdings have proportionally more influence on the average. This doesn't represent the actual buy or sell price. It is the split-adjusted average price of the securities as of the last day of the reported period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted. 2013 Q2 is the earliest period we have data for, so "2013 Q2*" means "2013 Q2 or earlier".